Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 28  |  Issue : 4  |  Page : 908-913

Evaluation of the role of antivascular endothelial growth factor in the management of pterygium

Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menofia Governorate, Egypt

Correspondence Address:
Mohamed H Tarawa
31111 Tanta
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-2098.173615

Rights and Permissions

Background Pterygium is a common condition. Many theories have been proposed for its pathogenesis, but excessive sun exposure is the most accepted. Studies show that immunostaining of vascular endothelial growth factor is more intensive in pterygial than in normal conjunctival sections. Objectives The aim of the study was to conduct a trial evaluating the role of antivascular endothelial growth factor in the management of pterygium. Materials and methods Fifty eyes with primary pterygium were included in a nonrandomized trial to evaluate the effect of subconjunctival bevacizumab before excision using the bare sclera technique. None of the eyes had any history of previous ocular disease or surgery. Eyes were examined at presentation, 3 weeks after injection, and 3 and 6 months postoperatively. Examinations included best-corrected visual acuity (BCVA), slit-lamp, and fundus examinations. Pterygium was assessed with regard to site, vascularity, horizontal length, and recurrence after 3 and 6 months. Recurrence was defined as any fibrovascular growth over the cornea 1 mm beyond the limbus. Results There were statistically significant results regarding age, sex, and occupation; 72% were male; the average age was 43.00 ± 13.47 years; 80% worked outdoors. The pterygia resolved with a postoperative recurrence rate of 36% after 6 months. After injection, there was no statistically significant difference regarding improvement in visual acuity. There was significant improvement in ocular irritation, inflammation (82.14%), and horizontal length. Preinjection length average was 2.99 ± 1.08 mm and postinjection length average was 1.78 ± 0.99 mm. Vascularity improved in all cases by one grade after injection. Before injection, 14 cases (28%) were grade I, 22 cases (44%) were grade II, and 14 cases (28%) were grade III. Three weeks after injection, 36 cases (72%) were grade I and 14 cases (28%) were grade II. Conclusion Subconjunctival bevacizumab is well tolerated without local or systemic side effects. The main effect was reduction of inflammation and vascularity of the pterygium with no effect on recurrence.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded94    
    Comments [Add]    

Recommend this journal